Business
CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury
MONMOUTH JUNCTION, N.J., May 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® and other
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., May 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world, announced the U.S Army Medical Research and Development Command has awarded CytoSorbents a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) contract, valued at $1,499,987 over 28 months, to advance development of the K+ontrol™ platform for the treatment of severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine. This follows the successful completion of the previously announced Phase I and Phase II SBIR programs for this application, totaling approximately $1.15 million in previous contract funding. \n\n \n \n \n \n \n \n\n \nCytoSorbents Awarded $1.5M SBIR U.S. Army Contract to Protect Wounded Warfighters From Deadly Complication of TraumaDr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, \"We greatly appreciate the continued support of the Defense Health Agency and U.S. Army of our innovative sorbent treatments for life-threatening hyperkalemia in severe trauma patients. Together with our collaborators, we have made excellent progress in developing potassium-lowering therapies that can be implemented by a medic without electricity, and have the potential to save lives in many scenarios where standard dialysis is not possible. We look forward to advancing these technologies to clinical usage to help our wounded warfighters and other mass casualty trauma victims.\"\nTrauma and crush injury to soft tissue can lead to rapid cell death and the release of a flood of intracellular potassium into the bloodstream. In compromised patients, very high levels of potassium in the blood, or severe hyperkalemia, can lead to dangerously irregular heartbeats called arrhythmias, and sudden cardiac death. This is particularly common in combat casualties, everyday civilian trauma, and mass casualty events such as earthquakes and terrorist bombings. Normally, hemodialysis is the definitive therapy to treat hyperkalemia. However, in remote locations, during prolonged field care in combat, in areas that lack modern medical facilities, or in situations where the numbers of vi...